BioSpace News Archive

Curis, Inc. today announced that the first mesothelioma patient has been enrolled and dosed in the Phase I study of CA-170.

Medicenna Therapeutics Corp. today announced two presentations at the Immuno-Oncology 360° Conference to be held February 6-8, 2019 at the Crowne Plaza Times Square, New York NY.

Pay-for-pounds pioneer HealthyWage bolsters challenge purportedly set forth by mom Kris Jenner, offers to pay Rob Kardashian an additional $50,000 cash for successfully shedding 50 pounds--no strings attached; Promoting the power of community-based motivation and support by spearheading a #HelpRobGetHealthy social media movement

Bristol-Myers Squibb Company announced today that its fourth quarter 2018 earnings call has been rescheduled for two hours earlier than previously announced.

Basilea Pharmaceutica Ltd. announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®), in patients with urothelial cancer. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study in mid-2019.

Amneal Pharmaceuticals, Inc. announced that the Company will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019, prior to the open of the U.S. financial markets.

Swedish Orphan Biovitrum AB announced today that it has completed the acquisition from AstraZeneca of rights to Synagis® (palivizumab) in the US as well as rights to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US, as announced on 13 November 2018.

Product from Infuse Your Life Health Products designed to support cardiovascular health

American Heart Month in February is a good time to take stock in your health, specifically your heart, and what you should do going forward.

Dr. Reddy’s Laboratories Ltd. today announced the launch of Propofol Injectable Emulsion, USP, a therapeutic equivalent generic version of DIPRIVAN (propofol) Injectable Emulsion, USP, approved by the U.S. Food and Drug Administration (USFDA).